Therapy Directory

Carboplatin clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Carboplatin as a study intervention. Browse Carboplatin recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1995

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Non-Squamous Non-Small Cell Lung Cancer, c-MET
Interventions: Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 18
States / cities: Chandler, Arizona • Duarte, California • Irvine, California + 15 more

Conditions: Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Cemiplimab, Chemoradiotherapy, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Surgical Procedure; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • Orange, California + 13 more

Conditions: Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 9
States / cities: Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 6 more

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Docetaxel, Gemcitabine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Questionnaire Administration, Sacituzumab Govitecan; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 162
States / cities: Phoenix, Arizona • Irvine, California • Orange, California + 127 more

Conditions: Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
Interventions: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF); Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Tucson, Arizona • Irvine, California • Orange, California + 9 more

Conditions: Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
Interventions: Vactosertib, Standard of Care Preoperative Therapy; Drug
Lead sponsor: Melissa Lumish; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 673
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more

Conditions: Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
Interventions: Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 11
States / cities: Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 8 more

Conditions: Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
Interventions: Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Certolizumab, Nivolumab, Paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan; Other · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 108
States / cities: Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more

Conditions: Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: Cabazitaxel and carboplatin, Lu-PSMA-617; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin, Etoposide Phosphate, Ibrutinib, Ifosfamide, Laboratory Biomarker Analysis, Rituximab, Utomilumab; Procedure · Drug · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Duarte, California

About this Carboplatin clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Carboplatin as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Carboplatin.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Carboplatin clinical trials

Filter and sort this therapy

Live official records

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

About this Carboplatin clinical trials directory page